help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Desideri, G.
Right arrow Articles by Ferri, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Desideri, G.
Right arrow Articles by Ferri, C.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 11 5341-5347
Copyright © 2003 by The Endocrine Society

Effects of Bezafibrate and Simvastatin on Endothelial Activation and Lipid Peroxidation in Hypercholesterolemia: Evidence of Different Vascular Protection by Different Lipid-Lowering Treatments

Giovambattista Desideri, Giuseppe Croce, Marzia Tucci, Gabriella Passacquale, Simona Broccoletti, Letizia Valeri, Anna Santucci and Claudio Ferri

Department of Internal Medicine and Public Health, University of L’Aquila, 67100 Coppito-L’Aquila, Italy

Address all correspondence and requests for reprints to: Giovambattista Desideri, M.D., Department of Internal Medicine and Public Health, University of L’Aquila, Blocco 11-Via Vetoio, 67100 Coppito-L’Aquila, Italy. E-mail: giovambattista.desideri{at}cc.univaq.it.

Hypercholesterolemia is combined with enhanced lipid peroxidation, which can promote atherogenesis by inducing endothelial adhesion molecule expression. Statins may protect vascular endothelium in hypercholesterolemia by reducing enhanced plasma levels of low-density lipoprotein and decreasing oxidative stress. Herein, we describe increased circulating levels of soluble intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin and total 8-iso-prostaglandin F2{alpha} (8-iso-PGF2{alpha}) concentrations, as indexes of endothelial activation and lipid peroxidation, respectively, in 67 hypercholesterolemic patients compared with 32 normocholesterolemic subjects. Significant cholesterol reductions were achieved in hypercholesterolemic patients after 6 months under either simvastatin (40 mg/d) or bezafibrate (800 mg/d) treatment, given according to a randomized double-blind trial. Simvastatin but not bezafibrate simultaneously reduced soluble adhesin and total 8-iso-PGF2{alpha} concentrations also. Vitamin E supplementation (400 IU/d) further reduced indexes of endothelial activation and lipid peroxidation in simvastatin-treated patients and significantly reduced the above indexes in bezafibrate-treated patients. Changes in circulating soluble adhesion molecule levels were directly correlated with changes in total 8-iso-PGF2{alpha} concentrations in simvastatin-treated patients also receiving vitamin E supplementation. All together, our data demonstrated that hypercholesterolemia was combined with endothelial activation and lipid peroxidation, which were efficaciously counteracted by simvastatin but not bezafibrate treatment. Thus, a different vascular protection can be achieved by different lipid-lowering treatments.

Abbreviations: CRP, C-reactive protein; HDL, high-density lipoprotein; ICAM-1, intercellular adhesion molecule-1; 8-iso-PGF2{alpha}, 8-iso-prostaglandin F2{alpha}; LDL, low-density lipoprotein; s, soluble; VCAM-1, vascular cell adhesion molecule-1.




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
B. Ky, A. Burke, S. Tsimikas, M. L. Wolfe, M. G. Tadesse, P. O. Szapary, J. L. Witztum, G. A. FitzGerald, and D. J. Rader
The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans
J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1653 - 1662.
[Abstract] [Full Text] [PDF]


Home page
Evid Based Complement Alternat MedHome page
K. Nozaki, H. Hikiami, H. Goto, T. Nakagawa, N. Shibahara, and Y. Shimada
Keishibukuryogan (Gui-Zhi-Fu-Ling-Wan), a Kampo Formula, Decreases Disease Activity and Soluble Vascular Adhesion Molecule-1 in Patients with Rheumatoid Arthritis
Evid. Based Complement. Altern. Med., September 1, 2006; 3(3): 359 - 364.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. Croce, G. Passacquale, S. Necozione, C. Ferri, and G. Desideri
Nonpharmacological treatment of hypercholesterolemia increases circulating endothelial progenitor cell population in adults.
Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): e38 - e39.
[Full Text] [PDF]


Home page
JAMAHome page
L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, J.-P. Cristol, and C. Colette
Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes
JAMA, April 12, 2006; 295(14): 1681 - 1687.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. Grassi, S. Necozione, C. Lippi, G. Croce, L. Valeri, P. Pasqualetti, G. Desideri, J. B. Blumberg, and C. Ferri
Cocoa Reduces Blood Pressure and Insulin Resistance and Improves Endothelium-Dependent Vasodilation in Hypertensives
Hypertension, August 1, 2005; 46(2): 398 - 405.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Desideri, M. De Simone, L. Iughetti, T. Rosato, M. L. Iezzi, M. C. Marinucci, V. Cofini, G. Croce, G. Passacquale, S. Necozione, et al.
Early Activation of Vascular Endothelial Cells and Platelets in Obese Children
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3145 - 3152.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Tenenbaum, E. Z. Fisman, and M. Motro
Bezafibrate and Simvastatin: Different Beneficial Effects for Different Therapeutic Aims
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1978 - 1978.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Desideri and C. Ferri
Authors' Response: Bezafibrate and Simvastatin: Different Beneficial Effects for Different Therapeutic Aims
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1978 - 1979.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society